KRAS testing looks at a tumor’s own DNA to see whether a gene that normally controls cell growth has been altered, the kind of change that keeps cancer cells growing. The result mainly guides which treatments are worth trying, rather than telling you whether cancer runs in your family. KRAS was long considered impossible to target with drugs, but some KRAS-driven cancers now have pills designed against them, which makes the test more useful than it used to be.1PubMed Central. Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer
What the KRAS Gene Does and Why a Mutation Matters
The KRAS gene makes a protein that works like a light switch inside cells, relaying “grow” signals from the cell surface to the nucleus.2MedlinePlus Genetics. KRAS gene The switch turns on when the protein picks up a small energy-carrying molecule, and it turns itself off by breaking that molecule down.3MedlinePlus Genetics. KRAS gene Cancer-linked mutations stop the protein from switching off, leaving it constantly active.4PubMed Central. KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy
Most of these mutations sit in a few spots. About 98% of KRAS mutations in cancer are single-letter changes at three places in the gene, called codons 12, 13 and 61.5PubMed Central. KRAS mutation: from undruggable to druggable in cancer A test can therefore find most KRAS mutations by checking a small number of known locations.
Reports name the exact change, such as G12C or G12D, rather than just saying “KRAS-positive.” The label tells you which spot changed and what it changed to. Different labels can mean different treatment options, so the exact name matters.
The KRAS change is almost always acquired by the tumor during life, not passed down in families. A positive result does not mean your children face a higher cancer risk. Rare inherited KRAS changes do exist, and they cause developmental conditions such as Noonan syndrome.
The result comes from a pathology or molecular lab report on the tumor sample. It tends to read like a line of gene names and letter-number codes rather than a plain yes or no. Because the test checks the tumor’s own DNA, it shows only changes found in the cancer cells, not the DNA you were born with. A report that says “no KRAS mutation detected” means the tumor’s KRAS gene has no change at the spots the test checks. It says nothing about other genes.
Which Cancers Need KRAS Testing
KRAS mutations are most common in pancreatic, colorectal and non-small cell lung cancer.6PubMed Central. Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts Up to 90% of pancreatic cancers carry one.7PubMed Central. Targeting KRAS in pancreatic cancer About 1 in 5 non-small cell lung cancers do, most often the G12C type.8PubMed Central. KRAS mutation: from undruggable to druggable in cancer
The lung figures apply to non-small cell lung cancer, the most common kind. KRAS testing is not usually done for small cell lung cancer. KRAS mutations are more common in people who smoke or used to smoke, but they also occur in people who never smoked, so smoking history alone does not decide who is tested. In advanced non-small cell lung cancer, testing happens before or at the start of treatment planning, because the result can open a targeted pill for the G12C change. If you were told your lung cancer is non-small cell and has spread, it is reasonable to ask whether KRAS is part of the tests already ordered. For colorectal cancer, the American Society of Clinical Oncology recommends KRAS testing for everyone whose cancer has spread, before starting cetuximab or panitumumab.9Oncology Times. ASCO Issues Preliminary Guidelines on KRAS Testing, New Mechanism for Providing Clinical Guideline Information
Advanced-stage cancer is the usual trigger because testing is typically ordered when choosing drug treatment rather than surgery alone. Early-stage cancers treated by surgery may not need it right away. Your oncologist may test when spread is found or when the cancer returns.
In pancreatic cancer, a KRAS finding is expected, so the more useful question is which exact change was found. Some pancreatic tumors have no KRAS mutation, and that result can point the care team toward looking for other treatable changes. Samples there are often small needle biopsies, so it helps to ask early that enough tissue be saved for testing.
Other cancers carry the mutation too. About 16% of endometrial (uterine) cancers do.10PubMed. KRAS mutations in endometrial cancers: Possible prognostic and treatment implications In bile duct cancer, KRAS mutations are linked to poorer survival, though the evidence is limited.11Eurasian Journal of Medicine and Oncology. Meta-analysis of the prognostic value of KRAS and TP53 mutations in cholangiocarcinoma For cancers outside the big three, KRAS testing is not a routine rule for everyone, and doctors may include it as part of a broader look at the tumor. If you have one of these cancers, ask whether KRAS is being checked as part of a wider panel or in connection with a clinical trial.
KRAS is also rarely tested alone. In colon cancer, doctors usually test it alongside genes like NRAS and BRAF. In lung cancer it is part of a broader panel that includes EGFR and ALK. It’s worth asking whether your test is a single-gene or panel test.
What a Positive or Negative Result Means for Treatment
In colorectal cancer, cetuximab and panitumumab help only people whose tumors have unchanged KRAS, which reports call “wild-type.”12PubMed Central. KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy A KRAS mutation keeps growth signals switched on further down the line, so blocking the receptor above it does little.13PubMed Central. KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy If your colorectal tumor has a mutation, these drugs are usually skipped, which spares you side effects and cost.
A mutation does not mean there is no treatment. Chemotherapy, and often other add-on drugs, remain options. The result mainly removes one drug family from the list rather than closing off care. If the result is wild-type, cetuximab or panitumumab become possible, but that does not guarantee they will work. Doctors usually check related genes such as NRAS and BRAF before choosing, because changes there can also affect whether these antibodies help.
In lung cancer, two pills that target the G12C change, sotorasib and adagrasib, have accelerated FDA approval.14PubMed Central. Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer15PubMed Central. Targeting KRAS in pancreatic cancer In previously treated lung cancer with that change, adagrasib shrank tumors in about 43% of people, with responses lasting a median 8.5 months.16PubMed. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation It also shrank brain metastases in about a third of people who had them.17PubMed. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation Many people still don’t respond, or the cancer later becomes resistant.18PubMed. The KRAS-G12C inhibitor: activity and resistance
These pills are taken by mouth at home, unlike infusion chemotherapy given at a clinic. They are generally used after earlier treatment has been tried, so the result may matter later in the plan even if it does not change the first treatment. Common side effects include digestive problems such as nausea or diarrhea, and your team will monitor liver tests and other labs while you take them.
The most common pancreatic KRAS changes, G12D, G12V and G12R, are not hit by current G12C pills.19PubMed Central. Targeting KRAS in pancreatic cancer Several G12D and pan-RAS drugs are in clinical trials, though.20PubMed Central. Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer A KRAS result in pancreatic cancer can help match you to one.
Retesting When Treatment Stops Working
In colorectal cancer that stopped responding to cetuximab or panitumumab, new KRAS mutations appeared in 6 of 10 cases.21PubMed Central. Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer These changes could show up in blood months before scans showed growth.22PubMed Central. Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer When adagrasib stops working, new KRAS or related gene changes are found in about 45% of people.23PubMed Central. Acquired Resistance to KRASG12C Inhibition in Cancer Resistance is expected, not a sign you did something wrong.
A repeat test is often a blood test rather than a new biopsy. A new KRAS change found this way can explain why a drug that once worked has stopped, which gives the team a reason for the change in plan instead of just a growing scan. Depending on what turns up, the options may include switching to a different drug, adding a drug, or looking at a clinical trial. Not every resistance change has a matching treatment yet, so retesting can sometimes explain the problem without offering a ready fix. A repeat test that finds no new change does not mean the drug is still working; scans and symptoms still guide decisions. If your cancer grows on treatment, ask whether retesting is planned.
How the Test Is Done, Tissue or Blood
Most testing uses tumor tissue saved from your biopsy or surgery, so you often need no new procedure. The tissue is usually left over from the biopsy that diagnosed the cancer, preserved in a small paraffin block that the pathology department keeps on file. If the biopsy was done at one hospital and you are treated at another, the lab can request the block or slides, which is routine but takes some coordination. If not enough tissue is left, your doctor may suggest a blood test or a new biopsy.
The lab pulls DNA from the tumor cells and reads the relevant genes, after a pathologist checks that the sample contains enough tumor. The result goes to your oncologist, who usually reviews it with you at a follow-up visit. Waits typically run one to a few weeks. Single-gene tests can return faster than broad panels.
Broad panel tests (your report may call this NGS, for next-generation sequencing) and single-gene tests give matching KRAS results most of the time, about 88 to 93%.24PubMed Central. Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer Panels can also find other targetable changes at once and avoid using up scarce tissue on repeated single tests, so it’s worth asking whether one is used. In advanced lung cancer, broad panel testing found more treatable changes and got people on the right treatment in about 2 weeks versus 5.25Journal of Clinical Oncology. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC)
A liquid biopsy finds tumor DNA in a blood sample.26PubMed. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer For you, it is an ordinary blood draw. It has limits, though. In colorectal cancer that has spread, a blood test caught only about 62% of mutations found in tissue.27PubMed. Liquid biopsy as a tool for KRAS/NRAS/BRAF baseline testing in metastatic colorectal cancer Blood and tissue agreed in about 3 in 4 stage IV tumors but in none at stage I.28PubMed. Concordance analysis between liquid biopsy (ctDNA) and tumor DNA molecular profiles from panel-based next-generation sequencing Blood tests work better when there is more cancer in the body, because more tumor DNA is shed into the blood. A negative blood result may therefore need confirming with tissue.
A blood test makes the most sense when tissue is hard to get, such as when a biopsy is risky or has already failed, or when speed matters. It also fits when checking for new changes during treatment, because it avoids another biopsy.
When the Test Fails or Can’t Give an Answer
In lung cancer samples, KRAS testing succeeded about 92% of the time.29PubMed Central. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer Needle biopsies through the chest wall failed about 27% of the time, and bone samples about 15%.30PubMed Central. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer Tissue stored more than 4 years was more likely to give invalid results.31PubMed Central. Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples
Too little tissue is the usual problem. Tests need enough tumor cells, and small needle biopsies may contain mostly normal cells or scar tissue, leaving too little tumor DNA. Older stored tissue can also break down over time, which makes the DNA harder to read. A failure says something about the sample, not about your cancer or anything you did.
Your doctor gets a “no result” or “insufficient” report. The options are retesting other stored tissue, a blood test, or a repeat biopsy, so ask which is quickest for your situation rather than going without. A repeat biopsy carries its own risks and recovery, so doctors weigh that against how much the result could change your treatment.
If treatment cannot wait, your doctor may begin standard therapy while the answer is pending, though some drug choices, such as cetuximab, depend on the result. Ask to be told when a new result is expected, so the gap does not stretch on without anyone tracking it.
Making Sure You Get Tested and Understand the Results
Testing is sometimes missed. People 65 and older and those in rural areas were less likely to get KRAS testing for colorectal cancer.32PubMed Central. KRAS biomarker testing disparities in colorectal cancer patients in New Mexico So were people on Medicaid or treated at community clinics.33PubMed Central. Biomarker Testing Disparities in Metastatic Colorectal Cancer If your cancer has spread, ask your oncologist directly whether KRAS testing has been done.
The best time to ask is when the cancer is found to have spread or returned, before the first drug treatment is chosen. If your plan is already set, it is still reasonable to ask whether testing was done and when the result will come. Asking the nurse or navigator to confirm that the pathology lab received the order can catch a missed step.
Results also affect how people feel. Biomarker results made about half of patients feel more confident in their care, but they raised stress for about 39%, often due to poor explanation.34Journal of Clinical Oncology. Communication of cancer biomarker testing results: What patients need Ask for a visit to go through the report, and bring someone with you. Ask the doctor to point to the exact line with the KRAS result and say in plain words what it means for you. If the report lists other genes, ask which ones affect your decisions now and which are just for information. Writing down the answers or asking to record the visit helps, since much of a diagnosis appointment is easy to forget.
Useful questions include:
- Has my tumor been tested for KRAS, and what exact change was found?
- Was it a panel or a single-gene test?
- Which treatments does this open or rule out?
- Are there clinical trials for my KRAS type?
Testing is generally covered for advanced colorectal and lung cancer. Ask about the lab’s billing before testing.